<DOC>
	<DOC>NCT00379249</DOC>
	<brief_summary>The primary objective of the study is to compare the effect of rosuvastatin therapy plus compliance initiatives and rosuvastatin therapy alone for 12 months (52 weeks) on long-term cumulative direct and indirect disease-related costs during the 36 month.</brief_summary>
	<brief_title>Rosuvastatin ORBITAL Germany</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>high cholesterol with an indication for cholesterollowering medication (statins) contraindications for statin therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>statin</keyword>
	<keyword>compliance</keyword>
</DOC>